Second Sight Receives FDA Approval to Begin Feasibility Study of Orion Cortical Visual Prosthesis System

September 1, 2017: By Joan McKenna

Second SightSecond Sight, maker of the Argus II retinal prosthesis system, announced Aug. 28 that it has received conditional approval from the US FDA to begin a feasibility study of its Orion Cortical Visual Prosthesis System.

The Sylmar, California, company may enroll up to five patients in total at two US sites: the University of California at Los Angeles and Baylor College of Medicine in Houston. The FDA has requested that the firm conduct additional device testing and address outstanding questions within 45 days.

Will McGuire, president and CEO of Second Sight, said in a statement: “The Orion team has met all major internal milestones this year, and we remain on track to achieve the company’s stated goal of implanting our first Orion patient before year end.”

Second Sight’s Orion is designed to convert images captured by a miniature video camera mounted on the patient’s glasses into a series of small electrical pulses. The Orion transmits these electrical pulses wirelessly to an array of electrodes implanted on the surface of the visual cortex. By bypassing the retina and optic nerve and directly stimulating the visual cortex, a cortical prosthesis system has the potential to restore useful vision to patients blinded due to many reasons, including glaucoma, diabetic retinopathy, or forms of cancer and trauma, the company said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Imprimis’ Q3-2017 Ophthalmic Revenues Increase 60 Percent, Total $4.9 Million

iVeena Completes Phase I/IIa Study of IVMED-10 for Post-Cataract Inflammation

RegeneRx Announces Positive Phase III Results for RGN-259 in Dry Eye

Bill Link, PhD, Joins LENSAR as Board Chairman

Apellis Prices $150 Million Initial Public Offering

Oculentis Recalls Lentis IOLs in Philippines Due to Reports of Postoperative Opacification

Valeant Reports 1 Percent Growth for Bausch + Lomb Segment in Q3-2017

Tivanisiran is Generic Name for Sylentis’ Dry Eye Candidate

Alimera’s Q3-2017 Revenues Increased 18 Percent; Company Sees Expanded Market for Iluvien

Iridex’ Revenues Increase 11 Percent in Q3-2017; 111 Cyclo G6 Systems, 7,800 G6 Probes Shipped

Glaukos’ Net Sales Increase 37 Percent in Q3-2017

Regeneron’s US Eylea Sales Increase 12 Percent in Q3-2017

Second Sight Reports Q3-2017 Net Sales of $1.6 Million, New $122,500 CMS Rate for Argus II

Tear Film Innovations, Exicure, Genisphere Complete Financing Rounds

Opternative Sues Warby Parker Over Online Eye Exams

Bausch + Lomb Receives US FDA Approval for Vyzulta for IOP Reduction in Glaucoma Patients

Allergan Plans Cost Cuts, Takes Impairment Charge as Restasis Generics Loom

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022